Tmem119

Manufactured by Merck Group

Sourced in United States

TMEM119 is a transmembrane protein that is expressed on the surface of microglia, the immune cells of the central nervous system. It is commonly used as a marker for the identification and analysis of microglia in various research applications.

Automatically generated - may contain errors

Lab products found in correlation

P stat3 tyr705, by Cell Signaling Technology (1 mentions) Cd11b, by Thermo Fisher Scientific (1 mentions) Vinculin, by Merck Group (1 mentions) Trem2, by Abcam (1 mentions) Stat3, by Cell Signaling Technology (1 mentions) P s6ser240 244, by Cell Signaling Technology (1 mentions) P 4e bp1 thr37 46, by Cell Signaling Technology (1 mentions) Nanog, by BioLegend (1 mentions) P akt ser473 and thr308, by Cell Signaling Technology (1 mentions) Mhcii, by BioLegend (1 mentions) 4e bp1, by Cell Signaling Technology (1 mentions) Granzyme b, by BioLegend (1 mentions) F4 80, by BioLegend (1 mentions) Cd62l, by BioLegend (1 mentions) Glial fibrillary acidic protein (gfap), by Merck Group (1 mentions) Mab377, by Merck Group (1 mentions) 3 amino 9 ethylcarbazole aec, by Merck Group (1 mentions) Brightvision plus kit, by Immunologic (1 mentions)

2 protocols using tmem119

Immunoassay Antibodies for Protein Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following antibodies were used for immunoassays: p‐S6 Ser240/244 (Cell Signalling, 5364 and 6520), S6 (Cell Signalling, 2217), p‐4EBP1 Thr37/46 (Cell Signalling, 2855), 4EBP1 (Cell Signalling, 9644), p‐AKT Ser473 and Thr308 (Cell Signalling, 9271 and 9275), AKT (Cell Signalling, 4691), p‐STAT3 Tyr705 (Cell Signalling, 4113 and BioLegend, 651021), STAT3 (Cell Signalling, 9139), p‐P65 (Cell Signalling, 3031 and 5733), P65 (Cell Signalling, 8242), Vinculin (Sigma, V4505), Iba1 (Wako, 019‐19741), CD11b (eBiosciences, 17‐0112‐82) and (Abcam, ab8878), CD45 (BioLegend, 103105), Ki67 (BioLegend, 652413), Granzyme b (BioLegend, 337221) and Perforin (BioLegend, 154406). IFNʏ (BioLegend, 505826), CD49d (BioLegend, 103618 and 304313), CD44 (BioLegend, 10349), CD62L (BioLegend, 104438), CD3 (BioLegend, 152303), CD4 (BioLegend, 100427), CD8 (BioLegend, 100722 and 100732), PU.1 (Cell Signalling, 2258), c‐kit (Abcam, ab212518), CD41 (BioLegend, 303702), CD235a (Life Technology, 14‐9987‐82), P2RY12 (Atlas, HPA014518 and 848006), TREM2 (Abcam, ab86491),TMEM119 (Sigma, HPA051870), MHCII (BioLegend, 107607), F480 (BioLegend, 123130), Sox2 (Santa cruz, sc‐17320) and NANOG (BioLegend 16H3A38).

Dumas A.A., Pomella N., Rosser G., Guglielmi L., Vinel C., Millner T.O., Rees J., Aley N., Sheer D., Wei J., Marisetty A., Heimberger A.B., Bowman R.L., Brandner S., Joyce J.A, & Marino S. (2020). Microglia promote glioblastoma via mTOR‐mediated immunosuppression of the tumour microenvironment. The EMBO Journal, 39(15), e103790.

+ Open protocol

+ Expand

Immunohistochemical Markers for Cell Identification

Check if the same lab product or an alternative is used in the 5 most similar protocols

For double‐labeling after ISH, slides were incubated for 1 h at room temperature with the following primary antibodies: mouse anti‐glial fibrillary acidic protein (GFAP; 1:4000, Sigma‐Aldrich, St. Louis, MO, USA), mouse anti‐NeuN (1:2000, MAB377, Chemicon, Temecula, CA, USA), rabbit anti‐ionized calcium binding adaptor molecule 1 (Iba1; 1:2000, Wako Chemicals, Neuss, Germany), mouse anti‐human leukocyte antigen (HLA‐DR/DP/DQ; 1:100, clone CR3/43 Agilent, Santa Clara, CA, USA), rabbit anti‐transmembrane protein 119 (TMEM119; 1:500, #HPA051870, Sigma‐Aldrich, St. Louis, MO, USA), mouse anti‐CD68 (1:200, clone KP1, Dako, Glostrup, Denmark) or rabbit anti‐CD8 (1:200, #7103, Dako, Glostrup, Denmark). Secondary horseradish peroxidase (HRP)‐conjugated antibodies (Brightvision plus kit, ImmunoLogic, Duiven, the Netherlands) were used. The visualization of the antibody‐antigen binding was done using 3‐amino‐9‐ethylcarbazole (AEC; Sigma‐Aldrich, St. Louis, MO, USA).

Korotkov A., Puhakka N., Gupta S.D., Vuokila N., Broekaart D.W., Anink J.J., Heiskanen M., Karttunen J., van Scheppingen J., Huitinga I., Mills J.D., van Vliet E.A., Pitkänen A, & Aronica E. (2020). Increased expression of miR142 and miR155 in glial and immune cells after traumatic brain injury may contribute to neuroinflammation via astrocyte activation. Brain Pathology, 30(5), 897-912.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!